These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 32530286)
1. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects. Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286 [TBL] [Abstract][Full Text] [Related]
2. 14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects. Ananthan S; Saini SK; Dersch CM; Xu H; McGlinchey N; Giuvelis D; Bilsky EJ; Rothman RB J Med Chem; 2012 Oct; 55(19):8350-63. PubMed ID: 23016952 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities. Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721 [TBL] [Abstract][Full Text] [Related]
4. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans. Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975 [TBL] [Abstract][Full Text] [Related]
6. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329 [TBL] [Abstract][Full Text] [Related]
7. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands. Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166 [TBL] [Abstract][Full Text] [Related]
8. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472 [TBL] [Abstract][Full Text] [Related]
9. Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists. Kumar V; Clark MJ; Traynor JR; Lewis JW; Husbands SM Bioorg Med Chem; 2014 Aug; 22(15):4067-72. PubMed ID: 24973818 [TBL] [Abstract][Full Text] [Related]
10. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability. Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782 [TBL] [Abstract][Full Text] [Related]
12. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models. Lei W; Vekariya RH; Ananthan S; Streicher JM J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990 [TBL] [Abstract][Full Text] [Related]
13. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability. Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands. Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161 [TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]